2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 997

The Effects of the Jak-Stat Signal Pathway Inhibition on Collagen Biosynthesis in Fibroblast Cell Culture

Cytokines and Cell Trafficking Poster

9:00AM-11:00AM: Abstract Number: 1543

The Efficacy, Safety and Adherence of Biologicbiological Disease-Modifying Anti Rheumatic Drugs, Infliximab, Tocilizumab and Abatacept, in Elderly Patients with Rheumatoid Arthritis

Rheumatoid Arthritis – Treatments Poster II: PROs, Safety and Comorbidity

9:00AM-11:00AM: Abstract Number: 1195

The Evaluation of the Small Enthesis of the Hands By Ultrasound: A Study on Healthy Subjects

Imaging of Rheumatic Diseases Poster II: Ultrasound

9:00AM-11:00AM: Abstract Number: 1100

The Frequencies and Molecular Profiles of CD16+ Monocyte Subsets in Patients with Systemic Lupus Erythematosus, Primary Antiphospholipid Syndrome, and Antiphospholipid Syndrome with Lupus, Identify Specific Clinical Features of These Diseases

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1634

The Impact of Comorbidities on Physical Function in Patients with Ankylosing Spondylitis and Psoriatic Arthritis Attending Rheumatology Clinics. Results of a National Study

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1220

The Impact of Gender on the Clinical Presentation, Management and Outcomes of Patients with Native Joint Septic Arthritis

Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 1192

The Impact of Participation in an Adalimumab (Humira) Patient Support Program on the Onset and Management of Disease Flares

Health Services Research Poster II – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 1191

The Importance of Quantitative Assessment of Joint/Organ Damage and Patient Distress in Addition to Inflammatory Activity in Routine Clinical Care

Health Services Research Poster II – ACR/ARHP

9:00AM-11:00AM: Abstract Number: 1262

The Importance of Standardization of Musculoskeletal Procedures Performed in an Academic Rheumatology Clinic

Measures and Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 1609

The Incidence Rate of Spondyloarthritis in Slovenia

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

9:00AM-11:00AM: Abstract Number: 1369

The Influence of Hand Osteoarthritis on Bone Microstructure and Biomechanical Properties of Radial Bone

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1694

The Lupus Severity Index Accurately Identifies Patients with Severe SLE in a Multi-Ethnic Cohort

Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 1500

The Multi-Biomarker Disease Activity Score Tracks Response to Rituximab Treatment in Rheumatoid Arthritis Patients

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1793

The Omeract Core Domain Set for Clinical Trials in Behçet’s Syndrome

Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1376

The Omeract-Oarsi Core Set of Outcome Domains to Measure in Clinical Trials for People with Hip and/or Knee Osteoarthritis

Osteoarthritis – Clinical Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].